An open label, prospective clinical comparative study to assess the anti-inflammatory benefit of momordica charantia tablet in metabolic syndrome. - not applicable

Dr M Shri Vidhya0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients already on OLmesartan 20mg OD and Metformin 500mgOD and Atorvastatin 10 mg OD
•2.Prediagnosed Metabolic syndrome patients with Diet and life style modifications
•3.Age >25 years
•4.Both Male and Female
•5.Triglycerides >150 mg/dl
•6.FBS >100 mg/dl
•7.PPBS >140 mg/dl
•8.BP >130/85 mmHg
•9.HbA1C -5.7-6.4

•1.Patients with Coronary artery disease /storke
•2.Patients with
•Aspirin/NSAIDS/Steroid/Febuxostat/Statin/Thaizide
•3.Patients with Injuries/Arthritis/Hypothyroidism/Nephrotic syndrome
•4.Patients on native treatment/ayurveda/siddha treatment/on any alternative treatment
•5.Pregnancy/Lactation/Heavy Alcohol Consumption
•6.Blood pressure >150/100mmHg
•7.HbA1C >7.4
•8.Triglycerides >400 mg/dl
•9.Patients on more than one drug for hypertension other than Olmesartan 20mg OD and drugs other than Metformin 500MG OD for Diabetes and drugs for elevated cholesterol other than Atorvastatin 10 mg OD

发起方

Dr M Shri Vidhya